|
|||||
|
|
Emerging EML4-ALK Variant 5 as a Concurrent Resistance Mechanism to Osimertinib in a Patient With EGFR E19del/T790M NSCLC |
|
| Institution: | 1. Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China;2. Division of Hematology/Oncology Department of Internal Medicine, University of California Davis School of Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, CA;3. Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China |
| Abstract: | |
| Keywords: | Acquired resistance EGFR mutation EML4-ALK Variant 5 Histologic transformation Metastatic NSCLC |
| 本文献已被 ScienceDirect 等数据库收录！ | |